Homepage Top Section2

As per terms of the deal, the former Cavion shareholders have secured an upfront payment of $52.5m (£43.5m). They are also eligible to receive additional payments of around

The company has announced positive OS results from the phase III randomised, double-blinded and multi-centre trial of Tagrisso in previously-untreated patients with locally-advanced or metastatic non-small cell lung

The agreements between GSK and Sabin in this regard are for advancing the development of the prophylactic candidate Ebola vaccines against the Ebola Zaire, Ebola Sudan and the

The study has achieved its co-primary endpoint of investigator-assessed progression-free survival (PFS). Roche’s combination of Tecentriq plus platinum-based chemotherapy demonstrated a statistically significant reduction in the risk of

The approval for Turalio is for the treatment of adults with rare joint tumour associated with severe morbidity or functional limitations and is not responsive to improvement through

The late-stage trial assessed the efficacy and safety of Kisqali plus fulvestrant combination in postmenopausal women having hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or

Under an all-stock Reverse Morris Trust transaction, each share of Mylan will be converted into one share of the new company. The deal allows Pfizer shareholders to own

Under the deal, Zambon has made an upfront payment of €140m (£125m) to acquire Breath Therapeutics and its subsidiaries and the acquisition value could increase to €500m (£446m)

The breakthrough therapy designation for the Keytruda, Lenvima combo is for the first-line treatment of patients with advanced unresectable HCC that is not responsive to locoregional treatment. Keytruda